SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr Reddys Laboratories informs about press release

21 Mar 2026 Evaluate
Dr Reddys Laboratories has informed that it enclosed a Press Release ‘Dr. Reddy’s Laboratories announces launch of India’s first DCGI-approved Semaglutide injection ‘Obeda’ for Type 2 Diabetes’.

The above information is a part of company’s filings submitted to BSE.

Dr. Reddys Lab Share Price

1279.95 12.90 (1.02%)
05-Jun-2026 09:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1806.95
Dr. Reddys Lab 1279.95
Cipla 1396.00
Zydus Lifesciences 1084.00
Lupin 2288.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×